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Introduction
Colorectal cancer (CRC) is the third most common cancer in 
men and the second most common cancer in women worldwide 
[1]. Data collected in 2008 showed that worldwide there were over 
1.23 million new cases, and over 608,000 patients died from CRC 
that year [2]. Several factors influence the prognosis, including 
clinical, histopathological, and biological factors related to the 
stage of the CRC tumor. Therefore, investigations into the molecu-
lar mechanisms of CRC that can lead to novel biomarkers to opti-
mize diagnosis and/or treatment regimens are essential. 
Ki67 expression has been shown to be strictly associated with 
cell proliferation. During interphase, the Ki67 antigen can be ex-
clusively detected within the cell nucleus, whereas in mitosis most 
of the protein relocates to the chromosomal surface. Ki67 protein 
is present during all active phases of the cell cycle (G1, S, G2, and 
mitosis), but is absent from resting cells (G0). Because of these 
qualities, Ki67 is an excellent marker to determine the growth frac-
tion of a given cell population, and likewise it could mark growing 
tumor cells [3].
Ki67 expression analysis is already used to estimate the progno-
sis of breast cancer and neuroendocrine tumors due to its expres-
sion pattern restricted to phases of the cell cycle in differentiating 
cells [4–6]. It was reported that liver metastases of CRC demon-
strated a significantly higher Ki67 labeling index (Ki67-Li) [7]. 
Ki67 expression was found to be significantly higher in tumor tis-
sues than in peritumoral tissues, and Ki67 levels were significantly 
associated with lymph node metastasis and poor prognosis of CRC 
[8]. However, some studies have shown that Ki67 has no correla-
tion with patient survival [9, 10]. We set out to investigate whether 
assessment of Ki67 could also help to more accurately define the 
prognosis for patients with CRC. 
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Summary
Background: Conflicting results have been reported 
about the association between the Ki67 labeling index 
(Ki67-Li) and clinical outcome in patients with colorectal 
cancer (CRC). Patients and Methods: Ki67 expression 
was assessed by immunohistochemistry (IHC) in 2,233 
consecutive CRC cases. Results: We determined 992 
cases to have a low and 1,241 cases to have a high Ki67-
Li (representing an approximately 44–56% breakdown in 
distribution between low versus high patients desig-
nated by phenotype). Stage III patients with a high Ki67-
Li had higher 3-year disease-free survival (DFS) and 
overall survival (OS) than those with a low Ki67-Li (DFS 
70 vs. 61%; p = 0.02 and OS 75 vs. 64%; p = 0.008). We 
also found significantly improved 3-year progression-
free survival (PFS) for stage IV patients in the high ver-
sus the low Ki67-Li group (PFS 14 vs. 10%; p = 0.02). Yet, 
we found no statistical differences in prognosis for stage 
I and II patients and in OS for stage IV patients between 
high versus low Ki67-Li (p > 0.05). Conclusion: Our re-
sults suggest that high Ki67-Li can be an independent 
prognostic biomarker to aid the assessment of patient 
outcomes in both stage III and IV CRC.
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Patients and Methods
Patients
The ethics committee of the Sun Yat-sen University Cancer Center ap-
proved this study, and informed consent was obtained from all patients at the 
beginning of the study. A total of 4,500 histologically confirmed CRC patients 
were recruited and 2,233 tumor tissues were obtained after operation for analy-
sis from the Sun Yat-sen University Cancer Center between May 2011 and May 
2016. All patients were of Chinese origin. The clinical and family histories of 
each patient were reviewed. Finally, 2,233 cases were selected for analysis fol-
lowing the outlined strict exclusion criteria: age less than 18 years and older 
than 85 years, severe complication, multiprimary cancer, synchronous and me-
tachronous CRC, family history (first-degree and second-degree relatives with 
any cancer), familial adenomatous polyposis, and death not from tumor-related 
causes. The primary tumor site was categorized as proximal colon if the tumor 
was located above the splenic flexure or distal colon if it was located at or below 
the splenic flexure and rectum. Stage I (T1–2 N0) and stage II (T3–4 N0) CRC 
patients without high-risk clinical features (e.g. T4 stage, bowel perforation or 
clinical bowel obstruction, inadequate lymph node sampling, poorly differenti-
ated history) were treated with radical surgery or endoscopic removal of the 
tumor alone. Stage II (T3–4N0) CRC patients with high-risk clinical features 
received chemotherapy comprising capecitabine; folinic acid+5-fluorouracil 
(5-FU)+oxaliplatin (mFOLFOX); and capecitabine+oxaliplatin (XELOX). Stage 
III (TxN1–2) patients received radical surgery and 12 cycles of adjuvant mFOL-
FOX/XELOX within a 6-month period. All stage IV (T×N×M1) patients with 
local tumor complications or resectable metastases received palliative surgery 
or radical surgery. The first-line treatment for stage IV CRC was the mFOL-
FOX/FOLFIRI (folinic acid+5-FU+irinotecan) regimen. 89 patients with rectal 
cancer also received neo-chemoradiotherapy. Responses were evaluated in ac-
cordance with the RECIST guidelines. After surgery, tumor recurrence was de-
tected by physical examination, serum carcinoembryonic antigen (CEA) assay, 
and abdominal and thoracic imaging; patients were monitored every 3–6 
months for the first 3 years, every 6 months for the following 2 years, and then 
annually for patients surviving beyond 5 years. The duration of follow-up was 
defined as the time between surgery and disease recurrence, death, or last hos-
pital contact (scheduled follow-up or telephone contact). The cutoff date for 
this analysis was May 2016. The median follow-up time for living patients in 
this study was 4.3 years. 
Immunohistochemical Staining for Ki67
All diagnosed CRC patients, independent of clinical criteria, were prospec-
tively tested using IHC for the expression of MMR proteins on the second day 
after operation. Blocks of formalin-fixed, paraffin-embedded adenocarcinoma 
tissue comprising an area of normal colorectal mucosa adjacent to the tumor 
were selected in each case. Staining for Ki67 tissue expression was performed 
using the primary anti-Ki67 antibody (1: 50 clone MIB-1; Dako, Tokyo, Japan). 
The Ki67-Li was calculated for each sample as the percentage of positively 
stained tumor cells among all counted tumor cells. Immunostained sections 
were evaluated by 2 pathologists blinded to the patients’ clinical characteristics. 
Discordant cases were reviewed by a third pathologist to reach a consensus. 
Ki67 had a moderate to intense reaction in most cases, both in well-differenti-
ated adenocarcinomas and in moderately or poorly differentiated tumors. Rep-
resentative examples of immunostaining are shown in figure 1. The mean per-
centage of positively stained cells for all cases was 47%. In our study, a percent-
age of < 50% positively stained tumor cells among all counted tumor cells was 
considered a low Ki67-Li, and a percentage of   50% was considered a high 
Ki67-Li, which was in concordance with previous studies [11]. 
Statistical Analysis
Data are described as frequencies given in percentage values. The differ-
ences in distribution between the variables examined were assessed with the Χ2 
or the Fisher’s exact test. The primary end point used in the analysis was dis-
ease-free survival (DFS) defined as the time from the date of surgery to the first 
event (local or distant disease recurrence), or progression-free survival (PFS) 
calculated as the time from the start of surgery to clinical or radiological pro-
gression. Patients who were alive and relapse-free at the last contact were cen-
sored at the time of last follow-up. Overall survival (OS) was defined as the time 
elapsed from the date of surgery until tumor-induced death. Surviving patients 
were censored at the time of last follow-up. Median follow-up and 95% confi-
dence intervals (CI) were calculated using the reverse Kaplan-Meier method. 
The survival curve was estimated using the Kaplan-Meier method and com-
pared using the log-rank test. Univariate and multivariate Cox proportional 
Fig. 1. Examples of immunostaining for Ki67.
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hazards models were used to explore associations between Ki67-Li, location, 
age, stage, differentiation grade, and gender. The score and likelihood ratio test 
p  values were used to test the statistical significance of each covariate in the 
univariate and multivariate Cox models, respectively. All statistical tests were 
two-sided, and p values  0.05 were considered statistically significant. Statisti-
cal analyses were performed using SPSS software (IBM Corp., Armonk, NY, 
USA).
Results
Of the 2,233 CRC patients evaluated, 992 were found to have a 
low Ki67-Li with an overall prevalence of 44.4%. 1,241 were found 
to have high Ki67 expression with a prevalence of 55.6%. This se-
lected patient population included 1,316 males and 917 females of 
which 32.8 and 22.8%, respectively, were found to present with a 
high Ki67-Li while the male versus female distribution of low Ki67-
Li was 26.2 and 18.3%, respectively. Detailed clinicopathological 
information for the patients included in this study is shown in 
table 1. In addition, we found that a high Ki67-Li was more likely 
to be noticed in the right (59.6%) or left (60.3%) colon versus the 
rectum (49.9%) (p <  0.001), and in older (40–59 years, 56.3%; 
60–85 years, 56.9%) versus younger (20–39 years, 46.3%; p = 0.028) 
patients. Gender, cancer stage, T (tumor) stage, N (lymph node) 
stage, M (metastasis) stage, and pathological differentiation 
showed no statistical differences in univariate Cox analysis (p 
> 0.05) for Ki67 expression. All parameters were dichotomy varia-
bles. Among the variables analyzed in the multivariate Cox model, 
age (hazard ratio (HR) 2.29, 95% CI 2.23–2.33, p = 0.025) and loca-
tion (HR 2.36, 95% CI 2.31–2.38, p = 0.020) were significantly as-
sociated with DFS. Age (HR 2.15, 95% CI 2.09–2.18, p = 0.022) and 
location (HR 2.40, 95% CI 2.36–2.43, p = 0.018) also had a statisti-
cally significant correlation with OS. 
Assessment of Ki67-Li as Prognostic Marker
Patients with stage III CRC and a high Ki67-Li had a statistically 
significant improvement in DFS (70%) and OS (75%) compared to 
patients with low Ki67-Li tumors (DFS 61%; HR 0.72, 95% CI 
0.55–0.95, p = 0.02 and OS 64%; HR 0.68, 95% CI 0.51–0.91, p = 
0.008). We also found significant improvement in the 3-year PFS 
for stage IV patients in the high Ki67-Li group (PFS 14%) versus 
the low Ki67-Li group (PFS 10%) (HR 1.23, 95% CI 1.04–1.57, p = 
0.02). However, OS showed no statistical difference in stage IV pa-
tients with high Ki67-Li tumors (OS 19%) versus low Ki67-Li tu-
mors (OS 18%) (HR 1.22, 95% CI 0.99–1.51, p = 0.06). From the 
analysis of stage I patients, we found no differences in the 3-year 
DFS or OS between high Ki67-Li patients versus those with a low 
Ki67-Li (DFS 94 vs. 93%; HR 0.84, 95% CI 0.35–2.03, p = 0.70 and 
OS 95 vs. 93%; HR 0.69, 95% CI 0.27–1.74, p = 0.43). Likewise, no 
difference was found in the 3-year DFS and OS of high versus low 
Ki67-Li stage II patients (DFS 83 vs. 78%; HR 0.77, 95% CI 0.57–
1.05, p = 0.09 and OS 85 vs. 81%; HR 0.82, 95% CI 0.59–1.13, p = 
0.22). The survival plots for Ki67-Li are shown in figure 2. 
Discussion
Here, we evaluated the expression of Ki67 in CRC tissues and 
whether assessment of the Ki67-Li could be a valuable prognostic 
tool in this disease. We found that a high Ki67-Li appeared to be an 
independent and good prognostic biomarker for survival in stage 
III and IV CRC patients while it provided no evidence for a prog-
nostic effect in stage I or II CRC patients. The reasons for the dis-
crepancies between the effect of Ki67 expression in the various 
CRC stages are not clear. However, the differences may account for 
the many roles of Ki67 in cell growth and regulation. 
It has been previously shown that the rate of tumor cell prolif-
eration can be assessed by detecting the fraction of cells with nuclei 
expressing Ki67 [6]. The Ki67 antigen binds to the nuclei of prolif-
erating cells throughout the cell cycle, except during the G0 and 
early G1 phases, marking cellular expansion [12]. Monitoring of 
the Ki67 protein has already been used as a clinical predictor for 
the prognosis of breast cancer and neuroendocrine tumors due to 
its expression pattern restricted to growth phases of the cell cycle 
found in differentiating cells [4, 5]. Nuclear staining of Ki67 was 
also shown to be significantly associated with disease-specific sur-
vival in a multivariate model of clear cell renal cell carcinoma and 
provided the ability to predict disease outcome [13]. It has also 
been reported that neoadjuvant chemoradiotherapy with cetuxi-
mab decreased the levels of Ki67-Li in rectal cancer [14]. With re-
gard to colon tissue, Ki67 was found to be highly expressed in the 
proliferative basal half of the crypt [15]. Also, it has been shown 
that Ki67 was significantly elevated in ulcerative colitis (UC) co-
lons compared to non-UC control samples, indicating that prolif-
eration is enhanced in UC colonic mucosa [16]. With regard to 
CRC itself, it has been reported that Ki67 expression correlates 
with patient age, pathological tumor differentiation, and lymph 
node involvement [17]. In addition, a strong correlation between 
Ki67 expression has also been seen in all levels of epithelial dyspla-
sia and tumor grades [18]. In another study, Ki67-Li was found to 
significantly correlate with lymph node metastasis, but not tumor 
size, age, or gender, in rectal adenocarcinomas [19]. It has also 
been shown that Ki67 expression is not related to atypia [20].
From our large dataset of Chinese CRC patients studied here, 
we found that high Ki67-Li correlated with old age and better sur-
vival for stage III or IV colon cancers, but not with gender, tumor 
stage, or pathological differentiation. Overall, the results of our at-
tempt to find an association between Ki67-Li and prognosis for the 
general population of patients with CRC were conflicting. Incon-
sistent effects of Ki67 expression with regard to patient outcomes 
also appear to have been evidenced in other studies. A previous 
study using Kaplan-Meier survival analysis showed that survival 
was significantly shorter for CRC patients with higher expression 
of Ki67 versus lower [21, 22]. Yet, lower TNM and Dukes stage and 
higher Ki67 expression and presence of Ki67 hot spot areas in his-
topathological samples in rectal carcinoma were associated with 
better survival rates [23]. High Ki67 expression was also found to 
correlate well with response of chemoradiation therapy in locally 
advanced rectal cancers [24]. In contrast to this finding, another 
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study showed that patients with high tumor regression actually had 
significantly lower Ki67 expression within their tumors than non-
responders [25]. Finally, well-differentiated adenocarcinomas from 
liver cancers were found to have a high number of low Ki67-Li ves-
sels that might account for differences in tumor growth [26]. 
Many of these earlier studies on the effects of Ki67 expression 
utilized only a small number of cases in their analysis. A more re-
cent study in CRC that analyzed 1,653 cases reported that high 
Ki67 expression is an independent prognostic marker for better 
survival [27]. The results of this earlier study are in slight contrast 
to those of the current study. In our study, we also found a high 
Ki67-Li to be an good independent prognostic biomarker but only 
for stage III or IV CRC patients. We found no prognostic effect for 
Ki67 indexing in stage I or II CRC patients. 
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Table 1. Clinicopathological characteristics of 
the patients
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One of the criteria that might account for the above differences 
is the classification of Ki67 indexing. The previous study stratified 
the patient groups into 3 categories of low, moderate, and high 
whereas we used only 2 designations of either high or low. Only 
17% of the previous study’s 1,653 patients were considered to have 
a high Ki67-Li. Second, our study was conducted in only 1 hospital 
in China, and this population may not be comparable to the previ-
ous study’s patient population nor does it necessarily reflect the 
entire population of China. Finally, CRC is a disease induced by 
multiple biological, genetic, and environmental factors that could 
account for differences in tumor response, and each of these ele-
ments should be examined in future studies. 
Conclusion
Our data demonstrate that patients with a high Ki67-Li have a 
statistically significant reduction in their rates of tumor recurrence 
as well as better survival rates compared to patients with a low 
Ki67-Li for stage III CRC. While no statistically significant differ-
ences were found for patients with stage I and II tumors and a high 
Ki67-Li, for stage IV CRC patients Ki67-Li was an effective prog-
nostic factor predicting PFS but not OS. Finally, we demonstrated a 
close correlation between high Ki67-Li and old age and colon can-
cer. This study provides further population-specific evidence for 
Ki67 expression in CRC and use of Ki67-Li monitoring for patient 
management.
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Fig. 2. Disease-free survival (DFS) and overall survival (OS) according to Ki67 expression in colorectal carcinoma (CRC) stage I–IV.
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